Skip to main content

Pharma News

 

Clinical courses

 

Clinical research courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Deeper understanding of malaria parasite sexual development unlocks opportunities to block disease spread

    For the first time, the developmental stages of the deadliest human malaria parasite have been mapped in high resolution, allowing researchers to understand this ever-adapting adversary in more detail than previously possible.

  • Scientists Track Doubling in Origin of Cancer Cells

    Working with human breast and lung cells, Johns Hopkins Medicine scientists say they have charted a molecular pathway that can lure cells down a hazardous path of duplicating their genome too many times, a hallmark of cancer cells.

    The findings, published May 3 in Science, reveal what goes wrong when a group of molecules and enzymes trigger and regulate what’s known as the “cell cycle,” the repetitive process of making new cells out of the cells’ genetic material.

  • Researchers Identify Biomarkers in Blood to Predict Liver Cancer
    Early detection has the potential to transform treatment and outcomes in cancer care, especially for cancers like liver cancer, which is typically diagnosed at a late stage with limited options for cure.
  • Tsetse fly protein provides anti-clotting agent with its own on-off switch
    Researchers at the University of Sydney and University of Geneva have developed a new anticoagulant, whose anticlotting action can be rapidly stopped ‘on demand’. The result could lead to new surgical and post-operative drugs that minimise the risk of serious bleeding.
  • EMA recommends marketing authorisation for Truqap
    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Truqap, intended for the treatment of locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations.
  • IIT Bombay unveils 10x GMP facility for pharma companies

    IIT Bombay unveils the nations first of  its kind GMP facility at any academic institution  The 10X GMP Facility at IIT Bombay is the first-of- its- kind in India and will help to manufacture products for human trials. This facility will encourage researchers to manufacture breakthrough products in healthcare which are 10 times cheaper or better or faster than anything currently available.

  • Lilly Q1 2024 increased by 26 percent driven by Mounjaro, Zepbound, Verzenio and Jardiance

    In Q1 2024, worldwide revenue was USD 8.77 billion, an increase of 26 percent compared with Q1 2023, driven by increases of 16 percent in volume and 10 percent due to higher realized prices. The volume increase was primarily driven by growth from Mounjaro, Zepbound, Verzenio and Jardiance, partially offset by declines in Trulicity.

  • Sanofi has launched GLP-1 drug in India
    Soliqua is indicated as treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.
  • Denmark to restrict Ozempic and other GLP-1 drugs for Diabetes
    Denmark rationalised cheaper diabetic medicines and restricted GLP-1 analogues. The so-called GLP-1 analogues, which include is known under the product names Ozempic, Trulicity, Rybelsus and Victoza, is significantly more expensive than other types of diabetes medication (so-called DPP-4 inhibitors, SGLT-2 inhibitors, beta-cell stimulants and metformin)
  • ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

    ONO Pharmaceutical, Co., Ltd and Deciphera Pharmaceuticals, Inc. announced that on April 29, 2024 (Japan time), ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for USD 25.60 per share in cash through a tender offer followed by a merger of a wholly owned subsidiary of ONO with and into Deciphera with Deciphera surviving as a wholly owned subsidiary of ONO.

Subscribe to Pharma News